Shorted

Mesoblast (MSB) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
24 Aug

ASX:MSB Mesoblast: Why Is Its Growth Story Back in Focus?

Highlights Mesoblast is drawing attention as its commercial-stage cell-therapy strategy becomes increasingly important to the company narrative. The biotechnology groups progress depends on commercial execution, regulatory pathways and the ability to expand adoption of its specialised therapies. Market attention is shifting from development milestones towards how effectively the company can translate its platform into a durable operating business. Australian biotechnology names can move quick...

Continue reading
Kalkine
Positive
23 Aug

Could Mesoblast (ASX:MSB), Telix (ASX:TLX) and Lindian (ASX:LIN) Stay in Growth Focus?

Highlights Mesoblast (ASX:MSB) remains in focus as its regenerative medicine pipeline advances through important clinical and commercial stages. Telix Pharmaceuticals (ASX:TLX) continues expanding its precision oncology platform across imaging and therapeutic applications. Lindian Resources (ASX:LIN) is progressing its rare earth development strategy as attention remains on diversified critical mineral supply chains. Australian growth shares continue attracting attention as investors look beyo...

Continue reading
Kalkine
Positive
23 Aug

Could Mesoblast (ASX:MSB), Westgold (ASX:WGX) and Lynas (ASX:LYC) Stay in Growth Focus?

Highlights Mesoblast (ASX:MSB) remains closely watched as its late-stage regenerative medicine programs progress through important clinical development stages. Westgold Resources (ASX:WGX) is drawing attention as operational expansion, mine development and integration shape its gold production profile. Lynas Rare Earths (ASX:LYC) remains exposed to growing strategic interest in non-Chinese rare earth supply chains and advanced materials. Australian growth shares remain an important area of mar...

Continue reading
Kalkine
Positive
23 Aug

Mesoblast (ASX:MSB) Leads 3 Australian Growth Stocks in Focus

Highlights Mesoblast, Telix Pharmaceuticals and Lindian Resources have emerged among closely watched Australian growth companies with notable insider ownership. Healthcare innovation and rare earth development continue to shape attention across the Australian share market. Each company faces unique operational milestones alongside sector-specific challenges that could influence future business progress. Australia's equity market continues to spotlight companies pursuing ambitious expansi...

Continue reading
Kalkine
Positive
21 Aug

Mesoblast (ASX:MSB) Leads 3 Australian Growth Stocks to Watch

Highlights Mesoblast, Predictive Discovery and Telix Pharmaceuticals are gaining attention for their growth-focused business strategies. Healthcare and gold sectors continue to attract market interest despite global economic uncertainty. Strong project pipelines and commercial progress remain central themes across these Australian-listed companies. Australia's share market continues to navigate a challenging global backdrop as central banks weigh future interest rate decisions and inflat...

Continue reading
Kalkine
Neutral
20 Aug

Are These Penny Stocks Worth Watching? MSB, CLOV and HYLN

Highlights Mesoblast (ASX:MSB) is advancing a focused cell therapy platform supported by regulatory progress and clinical development programs. Clover Health Investments (NASDAQ:CLOV) combines Medicare Advantage insurance with data-driven healthcare technology. Hyliion Holdings (NYSE:HYLN) is developing flexible distributed power technology through its KARNO Power Module. Balance sheet resilience remains particularly important for smaller companies that depend on external capital to support expa...

Continue reading
Kalkine
Neutral
11 Aug

Can Mesoblast (ASX:MSB) Prove Commercial Launch Manufacturing?

Highlights Mesoblast remains in focus as investors assess commercial launch and manufacturing readiness through research discipline, a key indicator of whether current momentum can translate into durable operating progress. August reporting season is sharpening attention on procedure demand and reimbursement quality, helping investors distinguish headline activity from the underlying quality of the business outlook. A key risk is that currency and labour costs can cloud underlying progress, whi...

Continue reading
Kalkine
Neutral
5 Aug

State Street Corporation Acquires 5.01% Stake in Mesoblast Limited, Becoming a Substantial Shareholder

Mesoblast Limited (ASX:MSB) has been notified of an initial substantial holding by State Street Corporation and its designated subsidiaries, revealing that the group attained substantial shareholder status on 3 August 2026, holding 5.01% voting power through 65,124,909 ordinary shares. Key Points State Street Corporation and its named subsidiaries became substantial holders in Mesoblast Limited as of 3 August 2026. The group holds a relevant interest in 65,124,909 ordinary shares, equating to...

Continue reading
Kalkine
Neutral
3 Aug

State Street Corporation and Subsidiaries End Substantial Holding in Mesoblast Limited (ASX:MSB)

Mesoblast Limited (ASX:MSB) announced that State Street Corporation along with its subsidiaries officially ceased to be substantial holders in the company as of 30 July 2026, based on a Form 605 Notice of Ceasing to be a Substantial Holder filed with the exchange on 3 August 2026. Key Highlights On 30 July 2026, State Street Corporation and its specified subsidiaries stopped being substantial holders in Mesoblast Limited. The prior substantial holding notice was submitted on 31 July 2026 and ...

Continue reading
Kalkine
Neutral
28 July

Could Mesoblast (ASX:MSB), Lynas (ASX:LYC) and WiseTech (ASX:WTC) Be Undervalued on Cash Flow?

Highlights Mesoblast, Lynas Rare Earths and WiseTech Global are drawing attention through cash-flow-based valuation assessments. Each company operates in a structural growth sector spanning biotechnology, critical minerals and logistics software. Commercial execution, funding discipline and long-term cash generation remain key themes for investors. Global markets continue navigating changing inflation expectations, evolving interest-rate outlooks and ongoing geopolitical uncertainty. In this e...

Continue reading
Kalkine
Neutral
27 July

Why Is Mesoblast (ASX:MSB) Back on the Radar?

Highlights Small-cap biotech names drew attention as clinical and regulatory milestones offered stock-specific catalysts. Cell-therapy developer Mesoblast anchored the theme as it advanced its commercial and pipeline ambitions. Imugene and Neuren Pharmaceuticals rounded out a small-cap biotech cohort tied to cancer and neurological therapies. Mesoblast (ASX:MSB) drew attention among the ASX small-cap biotech names today as the cell-therapy developer advanced its commercial and clinical ambiti...

Continue reading
Kalkine
Positive
25 July

Could Mesoblast (ASX:MSB), Lynas Rare Earths (ASX:LYC) and WiseTech Global (ASX:WTC) Be Entering Their Next Growth Chapter?

Highlights Mesoblast, Lynas Rare Earths and WiseTech Global continue advancing across biotechnology, critical minerals and logistics software. Product development, operational expansion and technology innovation remain key themes shaping investor interest. Healthcare innovation, rare earth demand and digital supply chain solutions continue influencing the outlook for these ASX-listed companies. Australian companies operating across healthcare, critical minerals and enterprise technology contin...

Continue reading
Kalkine
Neutral
24 July

State Street Global Advisors Ends Substantial Stake in Mesoblast Limited as of July 2026

State Street Global Advisors along with its subsidiary entities has officially ceased to be a substantial holder in Mesoblast Limited (ASX: MSB), the Sydney-based Australian regenerative medicine company. The fund manager’s relevant interest in the biotech firm dropped below the substantial holding threshold on 22 July 2026, following a sequence of share transactions and stock lending activities initiated in early March 2026. This marks a notable shift in institutional investor positioning wit...

Continue reading
Kalkine
Neutral
15 July

Why Are Mesoblast (ASX:MSB) and Supply Network (ASX:SNL) Suddenly Back on Value Watchlists?

Highlights Mesoblast (ASX:MSB) and Supply Network (ASX:SNL) have emerged among companies screening below estimates of their cash-flow worth. The two businesses represent very different sectors, highlighting how the value lens can uncover opportunities across the market. Renewed market volatility has encouraged investors to revisit companies trading below estimates of their intrinsic value. As market volatility continues to reshape sentiment, many participants are revisiting companies that appea...

Continue reading
Kalkine
Neutral
14 July

Mesoblast (ASX:MSB) Climbs as Global Biotech Dealmaking Heats Up

Highlights Global pharmaceutical dealmaking has rebounded to its busiest run in years, lifting sentiment across listed life sciences. Australian clinical-stage names are among the beneficiaries of renewed licensing and partnership appetite. A softer Tuesday open leaves the sector exposed to broader risk sentiment despite improving fundamentals. Australian life sciences shares have found an unlikely tailwind in a resurgent global dealmaking cycle, and Mesoblast Ltd (ASX:MSB), the cell therapy de...

Continue reading
Kalkine
Neutral
14 July

Mesoblast Announces Expiry of 1,237,237 MSBAI Employee Options Due to Unmet Vesting Conditions

Mesoblast Limited (ASX: MSB), the Australian cellular medicines firm specializing in inflammatory and cardiovascular disease therapies, has informed the market about the lapse of 1,237,237 unquoted MSBAI options following failure to meet vesting criteria. These options, classified under security code MSBAI and expiring on various dates with differing exercise prices, ceased on 7 July 2026, with the official company announcement submitted on 14 July 2026. This lapse decreases Mesoblast's outstand...

Continue reading
Kalkine
Neutral
13 July

Mesoblast (ASX:MSB) shares in focus as cell therapy revenue lands

Highlights A regenerative medicine name reported its first full year of commercial revenue from an approved cell therapy. The result landed as ASX healthcare names steadied at the start of a cautious trading week. Attention widened across biotech peers weighing clinical progress against rising costs. Mesoblast Limited (ASX:MSB), a regenerative medicine developer working with stem-cell platforms, stepped into the spotlight after reporting its first full year of commercial revenue from an approve...

Continue reading